Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2013 Springer-Verlag London. All rights are reserved. Recent years have seen significant advances in the technology available to study prostate cancer (PCa). Identification of processes that are frequently deranged in PCa has led to improved understanding of the pathogenesis and molecular biology of PCa. While much remains poorly understood, aberrant processes which render cancer cells susceptible to the effects of drugs have been identified; and attempts to manipulate these factors for therapeutic effect in patients are described as are cellular processes of importance in PCa. Demonstration of overactivity of specific signaling pathways in PCa and high-throughput development of drugs to target them have led to a large number of candidate therapeutic agents, many of which have demonstrated biological effects in cell culture and animal models. Clinical trials testing the effectiveness of these agents and these developments are summarized here demonstrating the impact of translational research. Novel biomarkers have also been described which may prove useful in particular settings such as in aiding diagnosis and early detection of disease. Our current understanding of the pathology of PCa metastases to bone is also described with reference to current and investigational therapies.

Original publication





Book title

Prostate Cancer: A Comprehensive Perspective

Publication Date



19 - 34